The Journal of Immunology · 2009 · 58 citations · 46 references
Life SciencesCell BiologyImmunologyCell TherapyCellular ImmunologyImmunotherapyAntigen RecognitionChimeric Antigen Receptor T-cell TherapyEffector T Cell FunctionT Cell ActivationT Cell BiologyGamma Delta T-cell TherapyMemory Recall ResponsesPersistenceReactivityT Cell Receptor EngineeringT Cell Receptor-engineered T CellsT-cell Receptor Engineered T-cell TherapyT-cell Receptor-engineered T Cells
The successful application of T cell-based immunotherapeutic applications depends on the availability of large numbers of T cells with the desired Ag specificity and phenotypic characteristics. Engineering of TCR-transferred T lymphocytes is an attractive strategy to obtain sufficient T cells with an Ag specificity of choice. However, the introduction of additional TCR chains into T cells leads to the generation of T cells with unknown specificity, due to the formation of mixed dimers between the endogenous and introduced TCR chains. The formation of such potentially autoaggressive T cells may be prevented by using gammadelta T cells as recipient cells, but the in vivo activity of such TCR-engineered gammadelta T cells has not been established. In the present study, we have investigated the in vivo functionality of TCR-transduced gammadelta T cells, in particular their Ag specific proliferative capacity, Ag specific reactivity, in vivo persistence, and their capacity to mount recall responses. The results demonstrate that alphabeta TCR engineering of gammadelta T cells forms a feasible strategy to generate Ag-specific effector T cells that do not express mixed TCR dimers. In view of increasing concerns on the potential autoimmune consequences of mixed TCR dimer formation, the testing of alphabeta TCR engineered gammadelta T cells in clinical trials seems warranted.
46
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Mark E. Dudley, John R. Wunderlich, Paul F. Robbins et al. · Science · 2002 · 2.8K citations · Full text
Life Sciences, Immunology, Oncology +17
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
Richard A. Morgan, Mark E. Dudley, John R. Wunderlich et al. · Science · 2006 · 2.6K citations · Full text
Medicine, Immunology, Oncology +14
HJ Kolb, A Schattenberg, JM Goldman et al. · Blood · 1995 · 2K citations · Full text
Medicine, Hematology, Immunology +16
Mark E. Dudley, John R. Wunderlich, James Chih‐Hsin Yang et al. · Journal of Clinical Oncology · 2005 · 1.6K citations · Full text
Medicine, Immunology, Oncology +17
H-J Kolb, J. Mittermüller, Ch. Clemm et al. · Blood · 1990 · 1.5K citations · Full text
Medicine, Hematology, Oncology +16